J. Gene Wang and the twenty years before year one

Twenty years is an unusually long preface to a first chapter. When J. Gene Wang co-founded Immetas Therapeutics in October 2018, he brought a working life that already included Merck, Abbott, GSK and Novartis. The new company had a beginning. Its chief executive had considerable experience before it.

Founding dates have a tidy appeal. They fit into a database field, sit comfortably on a timeline and suggest a moment when everything starts. Wang’s career makes that convention look a little underdressed. The company began in 2018; the education, development work and team leadership behind its co-founder reached much further back.

His story passes through Peking University and Yale, through established corporate organizations, and into a venture launched with Harvard professor David Sinclair. It subsequently acquires an investor, a new board member and a partner in South Korea. Follow those relationships and the biography becomes a story about how a working life crosses organizational boundaries.

There is a pleasing arithmetic to it: two degrees, four named corporate employers, two co-founders. Then comes the less symmetrical part, the work of turning a newly formed organization into something with financing and collaborators. A résumé can put all of this on one page. A calendar has to make rather more room.

A long preface, written at several institutions

Wang earned his MD at Peking University Medical Center and his PhD at Yale University. Those credentials place two universities in the opening chapters of his professional life. Later, Yale would appear again in a different setting, through its entrepreneurial network.

The two degrees also give his biography an international geography before the company story begins. Peking University is part of his academic background; Yale is both an academic connection and a later professional one. Neither belongs in the decorative small print. Together, they establish the institutions through which his training passed.

Education can look like a completed chapter once a career reaches the executive stage. In Wang’s case, the Yale connection remains visible beyond the degree. His name appears in Yale Ventures’ roster, and the university’s 2026 account of its entrepreneurial activity includes him in a discussion of the move from advising to operating.

Between academic training and founding came a corporate career of approximately twenty years. Merck, Abbott, GSK and Novartis are the four organizations named in that history. They give the pre-Immetas period a concrete shape: Wang worked within multiple established companies before co-founding an organization of his own.

That sequence matters to the chronology. The founder title arrived after years of professional work. It describes a subsequent responsibility, one added to an existing career. In a culture that enjoys the sudden arrival of an entrepreneur, Wang’s timeline offers the quieter pleasure of a long accumulation.

The résumé’s busy verb: led

Wang’s corporate responsibilities included creating development strategies and leading cross-functional teams. The phrase sounds thoroughly at home in a company biography. It is also more specific than a list of employers: it identifies work involving both plans and people.

There is an organizational story inside those responsibilities. A strategy describes how work is intended to proceed. A team supplies the people who carry it forward. Wang’s documented career includes both, placing him in the management of work across different professional functions.

The distinction is useful when reading an executive biography. A company name supplies context, but responsibilities tell us more about the person’s role inside it. In Wang’s case, the named activities are development strategy, team leadership and advancing programs between stages. These are the professional tasks that precede the founding chapter.

A résumé has an unfortunate habit of making twenty years look brisk. Four company names and a handful of verbs can compress an entire period into a paragraph. Here, the compression conceals the scale of the preface: Wang’s company-building story follows a substantial corporate working life.

Putting that experience beside the 2018 founding date changes the emphasis of the biography. The interesting transition is from working within established organizations to helping create a new one. Both appear in Wang’s record. The CEO title at Immetas belongs to the second setting, with the first still part of the story.

October 2018: two names on a beginning

Wang launched Immetas with David Sinclair in October 2018. Sinclair is a professor at Harvard. The founding partnership therefore brings Wang’s corporate background into an organization co-founded with an academic researcher.

The pairing is a concrete part of the company’s origin. Wang became co-founder and chief executive; Sinclair was identified as the other co-founder and a scientific adviser. Their roles put different responsibilities alongside one another at the beginning of the venture.

That is where the biography becomes relational. Wang’s working life now includes a named founding partner, alongside the universities and corporate organizations already in his background. Immetas supplies a new institutional address for that relationship.

The date is worth keeping precise. October 2018 is the launch month identified in Wang’s biography. September 2020 belongs to a subsequent financing announcement. Those two events occupy separate places on the timeline, with almost two years between them.

Company histories tend to acquire a gloss when their milestones are read backwards. An eventual financing announcement can make the founding look inevitable. A straightforward chronology preserves the sequence: first the company was launched by Wang and Sinclair, and later it announced outside capital. The dates do the telling without needing a retrospective flourish.

Eleven million dollars, and another chair at the table

On September 23, 2020, Immetas announced an $11 million Series A financing. Morningside Ventures was the sole investor in the round. The amount provides a memorable number; the investor’s identity makes the event specific.

The announcement also named a governance change. Lu Huang, a managing director at Morningside, joined the Immetas board in connection with the financing. Capital and a board appointment appeared together in the same chapter of the company’s history.

For a profile of Wang, the appointment belongs beside the funding total. His company’s network now included an investor and its representative on the board. A financing round is easier to understand when the people involved remain visible alongside the dollar sign.

Wang described the company’s approach in terms of managing uncertainty. He framed the strategy as an effort to reduce development risk. The wording establishes an intention. It provides a useful statement of approach without turning a financing announcement into a verdict on subsequent outcomes.

“This strategy is designed to reduce development risk”

J. Gene Wang · September 2020

There is a modest virtue in keeping those categories separate. An investment is an investment. A strategy is a strategy. A board appointment brings a named person into governance. Wang’s career story is clearer when each event retains its own meaning, instead of being bundled into the customary parade of triumphant adjectives.

The next relationship crossed an ocean

In October 2023, Immetas announced a research collaboration with GC Biopharma, based in Yongin, South Korea. The joint announcement was dated October 12. Wang was identified as Immetas’ co-founder and CEO.

The collaboration added another kind of relationship to the company’s history. Sinclair was a founding partner. Morningside was an investor. GC Biopharma became a collaborating organization. Those roles describe distinct ways of participating in the company’s work.

The agreement assigned responsibilities to the two organizations. Immetas’ contribution included identifying targets, characterizing its own research components and creating development strategies. GC Biopharma’s responsibilities included design, manufacture and work on delivery platforms. The announcement gave the partnership a division of work.

That allocation is the business detail to keep in view. A collaboration headline can be broad; an account of responsibilities makes the arrangement more concrete. Here, the parties described different contributions to a shared research effort.

For Wang, the 2023 announcement sits five years after the company’s launch. The chronology now has three distinct markers: company formation, financing and collaboration. It also has a wider geography, connecting a New Jersey company with a partner in South Korea. The corporate chapter of his biography has become a cross-border company story.

Yale returns to the page

Yale Ventures’ FY2026 report adds a later detail. In its discussion of entrepreneurs in residence moving from advising into operating, it names Gene Wang with Artelis. The report covers July 2025 through June 2026.

The mention places him within a continuing entrepreneurial network. Yale, already present in Wang’s academic history, appears again as an institution connecting experienced people with ventures. His career now reaches back into the university in a professional capacity.

It is a fitting place to leave the chronology open. Wang’s story includes education, corporate teams, a founding partnership, financing, governance and international collaboration. Artelis adds another named venture to the later record.

A company’s first year remains a convenient starting point. With Wang, the more interesting beginning sits earlier, in the long working life that preceded incorporation. Twenty years before year one is a considerable preface. It deserves to be read.